Herantis Pharma has initiated a non-invasive CDNF development program to broaden the application of CDNF in Parkinson’s disease and potentially other neurodegenerative disorders. In conjunction, Herantis and the University of Helsinki have signed a licensing […]
AbbVie’s Ibrutinib failed to meet its objective in a phase 3 trial DBL3001 in untreated diffuse large B-cell lymphoma patients. IMBRUVICA is a first-in-class Bruton’s tyrosine kinase inhibitor jointly developed and commercialized by Pharmacyclics LLC, […]
Herantis Pharma has initiated a non-invasive CDNF development program to broaden the application of CDNF in Parkinson’s disease and potentially other neurodegenerative disorders.In conjunction, Herantis and the University of Helsinki have signed a licensing agreement […]
Pfizer said that its breast cancer drug Ibrance (palbociclib) in combination with fulvestrant was not statistical significant in extending overall survival (OS) in a phase 3 Paloma-3 trial. The study assessed Ibrance in combination […]
A clinical trial, funded by Cancer Research UK, has shown that administering sodium thiosulphate (STS) after chemotherapy ‘cisplatin’ for the treatment of childhood liver cancer hepatoblastoma reduces hearing loss in children by almost 50%.Hepatoblastoma is […]